Working… Menu
Trial record 3 of 3 for:    Insmed | bronchiectasis

A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis (ASPEN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04594369
Recruitment Status : Recruiting
First Posted : October 20, 2020
Last Update Posted : April 26, 2021
Information provided by (Responsible Party):
Insmed Incorporated

Brief Summary:
The primary objective of this study is to evaluate the effect of brensocatib at 10 mg and 25 mg compared with placebo on the rate of pulmonary exacerbations (PEs) over the 52-week treatment period.

Condition or disease Intervention/treatment Phase
Non-Cystic Fibrosis Bronchiectasis Drug: Brensocatib 10 mg Drug: Brensocatib 25 mg Drug: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1620 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study
Actual Study Start Date : December 1, 2020
Estimated Primary Completion Date : March 2024
Estimated Study Completion Date : March 2024

Arm Intervention/treatment
Experimental: Brensocatib 10 mg
Participants will receive brensocatib 10 mg once daily, for 52 weeks.
Drug: Brensocatib 10 mg
Oral tablet.
Other Name: INS1007

Experimental: Brensocatib 25 mg
Participants will receive brensocatib 25 mg once daily, for 52 weeks.
Drug: Brensocatib 25 mg
Oral tablet.
Other Name: INS1007

Placebo Comparator: Placebo
Participants will receive a brensocatib-matching placebo once daily.
Drug: Placebo
Brensocatib-matching oral tablet.

Primary Outcome Measures :
  1. Rate of Pulmonary Exacerbations (PEs) [ Time Frame: 52 Weeks ]

Secondary Outcome Measures :
  1. Time to First Pulmonary Exacerbation (PE) [ Time Frame: 52 Weeks ]
  2. Percentage of Participants who are Pulmonary Exacerbation (PE) Free [ Time Frame: 52 Weeks ]
  3. Change from Baseline in Postbronchodilator Forced Expiratory Volume in 1 second (FEV1) Measurements [ Time Frame: Baseline to Week 52 ]
  4. Rate of Severe Pulmonary Exacerbations (PEs) [ Time Frame: 52 Weeks ]
  5. Change from Baseline to Week 52 in Quality of Life Questionnaire - Bronchiectasis (QOL-B) Respiratory Symptoms Domain Score [ Time Frame: Baseline to Week 52 ]
  6. Incidence and severity of treatment-emergent adverse events [ Time Frame: Up to Week 56 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Provide their signed study informed consent to participate.
  • Clinical history consistent with non-cystic fibrosis bronchiectasis (cough, chronic sputum production and/or recurrent respiratory infections) that is confirmed by chest computerized tomography (CT) scan.
  • At least 2 pulmonary exacerbations defined by need for antibiotic prescription by a physician for the signs and symptoms of respiratory infections in the past 12 months before the Screening Visit.
  • Women must be post-menopausal (defined as no menses for 12 months without an alternative medical cause), surgically sterile, or using highly effective double barrier contraception (ie, methods that in combination achieve <1% unintended pregnancy rates per year) from Day 1 to at least 90 days after the last dose.
  • Male participants with female partners of childbearing potential must be using effective contraception from Day 1 to at least 90 days after the last dose.

Exclusion Criteria:

  • A primary diagnosis of chronic obstructive pulmonary disease (COPD) or asthma as judged by the Investigator.
  • Bronchiectasis due to cystic fibrosis.
  • Current smokers as defined per Centers for Disease Control (CDC).
  • Known or suspected immunodeficiency disorder, including history of invasive opportunistic infections.
  • Known history of human immunodeficiency virus (HIV) infection.
  • Currently being treated for nontuberculous mycobacteria (NTM) lung infection, allergic bronchopulmonary aspergillosis, or tuberculosis (TB).
  • Active and current symptomatic infection by COVID-19.
  • Inability to follow the procedures of the study (eg, due to language problems or psychological disorders).
  • Receiving medications or therapy that are prohibited as concomitant medications.
  • Previously participated in a clinical trial of brensocatib.
  • Received any live attenuated vaccine within 4 weeks prior to the first administration of brensocatib.
  • Suffering an exacerbation 4 weeks before Screening or during the Screening period.
  • Unable to comply with ≥75% of completion of electronic diary entries or have compliance issues during the Screening Period.
  • Participated in any other interventional clinical studies within 3 months before Screening Visit.
  • History of alcohol or drug abuse within 6 months prior to the Screening Visit.
  • Is the Investigator or any Sub-Investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04594369

Layout table for location contacts
Contact: Insmed Medical Information 844-4-INSMED

Show Show 140 study locations
Sponsors and Collaborators
Insmed Incorporated
Layout table for additonal information
Responsible Party: Insmed Incorporated Identifier: NCT04594369    
Other Study ID Numbers: INS1007-301
2020-003688-25 ( EudraCT Number )
First Posted: October 20, 2020    Key Record Dates
Last Update Posted: April 26, 2021
Last Verified: April 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Insmed Incorporated:
Additional relevant MeSH terms:
Layout table for MeSH terms
Pathologic Processes
Bronchial Diseases
Respiratory Tract Diseases